Repros Therapeutics Inc. (NASDAQ:RPRX) was downgraded by investment analysts at Laidlaw from a “buy” rating to a “neutral” rating in a report released on Friday.
Repros Therapeutics (NASDAQ:RPRX) opened at 0.3701 on Friday. The company has a 50-day moving average price of $0.44 and a 200-day moving average price of $0.94. The stock’s market cap is $9.89 million. Repros Therapeutics has a one year low of $0.30 and a one year high of $2.48.
Repros Therapeutics (NASDAQ:RPRX) last posted its quarterly earnings data on Tuesday, May 9th. The biotechnology company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by $0.08. The business had revenue of $0.01 million during the quarter. Repros Therapeutics had a negative return on equity of 276.50% and a negative net margin of 49,564.86%. On average, analysts anticipate that Repros Therapeutics will post ($1.07) earnings per share for the current year.
An institutional investor recently raised its position in Repros Therapeutics stock. Allegis Investment Advisors LLC boosted its position in Repros Therapeutics Inc. (NASDAQ:RPRX) by 6.3% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 366,190 shares of the biotechnology company’s stock after buying an additional 21,703 shares during the period. Allegis Investment Advisors LLC owned 1.37% of Repros Therapeutics worth $439,000 as of its most recent SEC filing. Institutional investors and hedge funds own 21.71% of the company’s stock.
Repros Therapeutics Company Profile
Repros Therapeutics, Inc is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company’s product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis.
Receive News & Ratings for Repros Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repros Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
